Science

Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment

Sergio Cifuentes/X

Mar 3, 2025, 11:35

Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment

Sergio Cifuentes, Cancer Research Project Manager at CENEIT Mexico, shared a post on X about a paper by Mohamed Gouda et al. published in Clinical Cancer Research:

“Resistance to T-DXd:

HER2 loss: 32.4%
HER2 decrease expression: 29.4%

Reevaluation of HER2 status following T-DXd treatment should be considered prior to alternate HER2-targeted therapies.”

“Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer”

Authors: Mohamed Gouda, Amrit Gonugunta, Ecaterina Dumbrava, Hui Chen, Funda Meric-Bernstam et al.

Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment

More posts featuring Sergio Cifuentes.

Amrit Gonugunta Breast Cancer cancer Ecaterina Dumbrava Funda Meric-Bernstam Hui Chen Mohamed Gouda OncoDaily Oncology Sergio Cifuentes Trastuzumab deruxtecan

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders